Taking all the evidence together, there is a need for consideration of GLP-1 RA as a potential agent for primary prevention clinical trial in low risk of cardiovascular, renal diseases, overweight, or even healthy population with research design focusing on both cardiovascular outcomes and cardiovascular risk reduction. The gene discussed is GCG; the disease is kidney disorder.